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Vasopressin type 2 receptor (V2R) belongs to the vasopressin (VP)/oxytocin (OT) receptor 
subfamily of G protein-coupled receptors (GPCRs), which comprises at least four closely related 
receptor subtypes: V1aR, V1bR, V2R, and OTR.1 These receptors are activated by arginine 
vasopressin (AVP) and OT, two endogenous nine-amino acid neurohypophysial hormones, which 
are thought to mediate a biologically conserved role in social behavior and sexual reproduction.2 
V2R is mainly expressed in the renal collecting duct principal cells and mediates the antidiuretic 
action of AVP by accelerating water reabsorption, thereby playing a vital role in controlling water 
homeostasis. Moreover, numerous gain-of-function and loss-of-function mutations of V2R have 
been identified and are closely associated with human diseases, including nephrogenic syndrome 
of inappropriate diuresis (NSIAD) and X-linked congenital nephrogenic diabetes insipidus (NDI).3 
Thus, V2R has attracted intense interest as a drug target. However, due to a lack of structural 
information, how AVP recognizes and activates V2R remains elusive, which hampers the V2R-
targeted drug design. Here, we determined a 2.6 Å resolution cryo-EM structure of the full-length, 
Gs-coupled human V2R bound to AVP (Fig. 1a; Supplementary information, Table S1). The Gs 
protein was engineered based on mini-Gs that was used in the crystal structure determination of 
the Gs-coupled adenosine A2A receptor (A2AR) to stabilize the V2R–Gs protein complex 
(Supplementary information, Data S1).4 The final structure of the AVP–V2R–Gs complex contains 
all residues of AVP (residues 1–9), the Gαs Ras-like domain, Gβγ subunits, Nb35, scFv16, and the 
V2R residues from T31 to L3398.57 (superscripts refer to Ballesteros–Weinstein numbering5). The 
majority of amino acid side chains, including AVP, transmembrane domain (TMD), all flexible 
intracellular loops (ICLs) and extracellular loops (ECLs) except for ICL3 and G185–G188 in 
ECL2, were well resolved in the model, refined against the EM density map (Fig. 1a; 
Supplementary information, Figs. S1–3). The complex structure can provide detailed information 
on the binding interface between AVP and helix bundle of the receptor, as well as the receptor–Gs 
interface. 
AVP occupies an orthosteric binding pocket in the TMD bundle composed of all TM helices 
and ECLs (Fig. 1b, c; Supplementary information, Table S2). The most notable conformational 
feature of AVP is the tocin ring formed by a disulfide bridge between the first and sixth cysteine 
residues, presenting a “spoon-like” conformation (Supplementary information, Fig. S4a, b). The 
cyclic spoon head inserts deeply into the TMD core, while the C-terminal spoon tail stretches 
toward the ECLs of the receptor. Cys1P of AVP and Q962.61, K1163.29, Q1193.32 of V2R form a 
stabilizing H-bond network, consistent with the decreased potency of the receptor mutants with 
these residues mutated (Fig. 1b; Supplementary information, Fig. S4c, d). The hydroxyl group of 
Tyr2P H-bonds to the main chain oxygen of L3127.40, whereas its main chain CO group forms 
another H-bond with Q1744.60 (Fig. 1b; Supplementary information, Fig. S4c). Phe3P buries in a 
hydrophobic cleft constituted by M1203.33, M1233.36, Y2055.38, V2065.39, I2095.42, F2876.51, F2886.52, 
and Q2916.55 (Fig. 1b; Supplementary information, Fig. S4c). Other polar contacts are seen 
between Gln4P and R2025.35, Gln4P and the backbone and side chain oxygens of Q2916.55, as well 
as Asn5P and the main chain of A194ECL2 (Fig. 1b, c; Supplementary information, Fig. S4c). Arg8P 
forms salt bridges with D331.28 and E401.32, the latter forms an extra salt bridge with K1001.32 (Fig. 
1c; Supplementary information, Fig. S4c). Additionally, the C-terminal amide of AVP points to 
ECL1, stacking against the R104ECL1 guanidinium group and H-bonding to the backbone CO group 
of D103ECL1 (Fig. 1c; Supplementary information, Fig. S4c). These interactions between AVP and 
residues in V2R binding pocket were confirmed through alanine mutagenesis studies using cAMP 
accumulation assays (Supplementary information, Fig. S4d–g and Table S4).  
This structure also provides a template to study the selectivity of AVP and OT. OT has two 
amino acid substitutions (Phe3P to Ile3P and Arg8P to Leu8P) (Supplementary information, Fig. S5a), 
and exhibits a much lower selectivity against V2R as opposed to AVP.6 By docking OT into the 
V2R binding pocket, a weaker hydrophobic interaction network is created for Ile3P compared to 
its equivalent residue Phe3P in AVP (Supplementary information, Fig. S5b). Additionally, the 
hydrophobic leucine at position 8 no longer shows the polar interactions with the receptor as 
compared with Arg8P of AVP (Supplementary information, Fig. S5c). Thus, the peptide-binding 
pocket of V2R defines a relatively unfavorable binding environment for OT in contrast to AVP.  
A “DCWA” sequence in ECL2 is highly conserved throughout VP/OT receptor sub-family but 
is not a feature of other class A GPCRs.7 Interestingly, structural comparison of the AVP–V2R–
Gs complex with inactive OTR (PDB: 6TPK)
8 reveals a notable conformational transition of ECL2 
from β-hairpin to a flexible loop (Fig. 1d). In this conserved sequence, W193ECL2 and A194ECL2 
directly contact with AVP. Asn5P may push and stack against W193ECL2 and overcome the probable 
steric clash between Asn5P and W188ECL2 of OTR, the cognate residue of V2R, which may confer 
this conformational transition (Fig. 1d). Although D191ECL2 and C192ECL2 do not directly interact 
with AVP, the former forms an H-bond to the F105ECL1 amide and a salt-bridge to R104ECL1 and 
the latter forms a conserved disulfide bond with C1123.25. These interactions, in turn, stabilize 
ECL1 and ECL2 conformations, thereby facilitating the interactions between ECL1 and the C-
terminal amide of AVP (Fig. 1e; Supplementary information, Fig. S4f, g and Table S4).  
A structural comparison of the AVP–V2R–Gs complex with the inactive OTR supports the 
contention that our structure is indeed in the active state. AVP triggers the rotameric change of 
“toggle switch” W2846.48, initiating the rotation and a notable outward displacement of TM6, the 
hallmark of GPCR activation (Fig. 1f; Supplementary information, Fig. S6a).9 Intriguingly, a 
distortion of TM7 helix was observed between L3127.40 and S3157.43. This distorted conformation 
appears to be stabilized by the H-bond between Tyr2P of AVP and the main chain CO group of 
L3127.40 in the receptor, drawing TM7 toward the peptide-binding pocket core (Fig. 1g). 
[Phe2]AVP, a synthesized AVP analog with a substitution of Tyr by Phe that abolishes this H-
bond, showed decreased agonistic activity by 28-fold,10 implying that the polar interaction between 
Tyr2P and the receptor is critical to AVP-induced V2R activation. Specifically, F6.44 and I3.40, 
residues in the conserved “P-I-F” motif in class A GPCRs, are substituted by polar residues 
Y2806.44 and S1273.40 in V2R, respectively (Fig. 1h). AVP binding triggers the rotation of Y2886.44 
relative to the inactive OTR (Fig. 1i), subsequently forming a featured H-bond network between 
Y2806.44/S1273.40 and the backbone CO group of V2135.46 in contrast to active β2AR (PDB: 
3SN6),11 which probably stabilizes the active conformation of the receptor (Fig. 1j). The disease-
associated mutations S1273.40F and Y2806.44C in V2R deactivate the receptor,12,13 while the 
replacement of F2846.44 in OTR by the V2R-equivalent tyrosine converts AVP from a partial to a 
full agonist,14 supporting the hypothesis that these unconventional “P-I-F” residues play critical 
roles in V2R activation. Furthermore, the cytoplasmic end of TM4 is one helical turn shorter than 
that of the inactive OTR,8 Gs-coupled β2AR
11 and A2AR
4 (PDB: 5G53), thereby releasing a longer 
ICL2. The ICL2 protrudes towards TM1 and adopts a C-shaped conformation (Supplementary 
information, Fig. S6b). This C-shaped loop is stabilized by H-bonds formed between H802.45 and 
the backbone CO group of H155ICL2, as well as W71ICL1 and backbone CO group of A154ICL2, and 
further by an intra-loop polar interaction network (Supplementary information, Fig. S6c–e), which 
may maintain ICL2 in a specific conformation and probably affect the ICL2–Gαs interaction 
pattern. 
TM5 and TM6 with the outward movement of the cytoplasmic ends open a cytoplasmic cavity 
together with TM2, TM3, and helix 8 to accommodate the α5 helix of Gαs, constituting a major 
V2R–Gs interface (Supplementary information, Fig. S7a). One additional interface relates to ICL2 
that interacts with α5 helix, αN-β1 junction, and the top of the β3-strand of Gαs, presumably 
stabilized by hydrophobic contacts (Supplementary information, Fig. S7b). In contrast to the Gs-
coupled β2AR and A2AR structures, the cytoplasmic ends of TM5 and TM6 in V2R display a 
smaller amplitude of outward displacements (5.8 Å for TM5 and 8.7 Å for TM6 relative to β2AR,
11 
2.5 Å for TM5 and 7.2 Å for TM6 relative to A2AR,
4 measured at Cα carbon of residues 5.67 and 
6.30, respectively) (Fig. 1k, l). Also, a noticeable shift of Gs protein in the AVP–V2R–Gs complex 
may partly be caused by relatively inward positions of TM5 and TM6 that push the entire Gs 
heterotrimer shifts in the same direction. Besides, the α5 helix of Gαs in the AVP–V2R–Gs 
complex shifts half a helical turn away from the 7TM core (Fig. 1k). These structural differences 
altogether create a smaller cytoplasmic cavity to accommodate Gs protein. Indeed, the solvent-
accessible surface area (SASA) of the V2R–Gαs interface (943.32 Å
2) is smaller than that of β2AR–
Gαs (1,030 Å
2) and A2AR–Gαs interfaces (1,276 Å
2) (Supplementary information, Fig. S7c). 
Interestingly, compared to Gs-coupled β2AR and A2AR, V2R exhibits a 1–2 helical turns shorter 
TM5 cytoplasmic end, which may be caused by a consecutive P-G-P sequence (P238, G239, and 
P240, residues known as α-helix breakers), resulting in fewer interactions between TM5 of V2R 
and Gαs subunit (Fig. 1l; Supplementary information, Fig. S7d and S8). 
In conclusion, we solved the cryo-EM structure of Gs-coupled V2R bound to its endogenous 
ligand AVP. In this complex, AVP presents a unique cyclic conformation formed by an 
intramolecular disulfide bond and engages the orthosteric binding pocket of V2R in a ligand-
specific mode. AVP-induced distortion of TM7 and a unique polar network formed by equivalent 
residues in the “P-I-F” motif may differentiate activation of V2R from other class A GPCRs. A 
smaller amplitude of the outward displacement of TM5 and TM6 and the concomitant shift of Gs 
protein not only distinguish V2R from its counterparts but also represent a diversified Gs coupling 
mechanism. Additionally, our structure is valuable to the mechanistic understanding of V2R 
mutation-associated diseases (Supplementary information, Fig. S9), while systematic 
investigations are required to enrich our knowledge in this regard. Together, our findings provide 
a framework for understanding AVP recognition and V2R activation, thereby offering a structural 
template for drug design targeting V2R. 
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Fig. 1 Cryo-EM structure of the AVP–V2R–Gs complex. a Orthogonal view of the density map 
(left panel) and model (right panel) for the AVP–V2R–Gs complex. V2R, slate blue; AVP, green; 
Gs, orange; Gβ, salmon; Gγ, cyan; Nb35, gray; scFv16, magenta; cholesterols, yellow. b, c 
Interactions between AVP and residues in V2R-binding pocket. d, e A comparison of the 
conformational change of ECL1 and ECL2 in AVP-bound V2R structure and retosiban-bound 
OTR (PDB: 6TPK) inactive structure. f Conformational changes of TM6 and conserved W6.48 and 
Y/F6.44 of V2R compared to inactive OTR. Red arrows indicate the movement of TM6 and the side 
chains of W6.48 and Y/F6.44 in V2R relative to inactive OTR. g Conformational change of TM7 in 
AVP–V2R structure relative to inactive OTR, β2AR–Gs, and A2AR–Gs structures. Red arrow 
indicates the movement of TM7 in V2R. h Sequence comparison of conserved P5.50-I3.40-F6.44 motif 
among V2R, V1aR, V1bR, OTR A2AR, and β2AR. Polar residues are colored in red and nonpolar 
residues in green. i, j Conformational changes of AVP-bound V2R structure resulted from 
substitutions in the conserved P5.50-I3.40-F6.44 motif relative to inactive OTR (i) and active β2AR (j) 
structures, respectively. k, l A conformational comparison of receptor helical bundle and Gαs α5 
helix among AVP–V2R–Gs, β2AR–Gs, and A2AR–Gs complexes. Red arrows indicate the 
movements of intracellular tips of TMs5, 6, and α5 helix of Gαs from V2R–Gs relative to other 
complexes. Black arrows label the cytoplasmic ends of TM5 in these structures. H-bonds and salt 
bridges are depicted as red and green dashed lines, respectively. The disulfide bonds are shown as 
yellow sticks. The structural alignment is based on receptors. 
 
